BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 22, 2008
 |  BioCentury  |  Emerging Company Profile

Proteostasis: One drug, many diseases

Emerging Company Profile

Parts of the proteostasis network, such as chaperones, folding enzymes, and the proteasome and degradation processes, are well known and have been targeted by many companies seeking to treat diseases of protein misfolding and aggregation. Proteostasis Therapeutics Inc. is taking a different tack, developing small molecules that recalibrate the network itself.

The company believes targeting the proteostasis network as a whole has the potential advantage of treating more than one disease with the same drug.

The proteostasis network comprises regulatory pathways governing synthesis, folding, aggregation, trafficking and degradation. Proper protein folding and degradation also minimize aggregation.

"We have a high-level understanding of the signaling...

Read the full 531 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >